Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10196239 | 0.87 | ROCK2 (0.67) | ROCK2CYP3A4CYP2C9ROCK1LMNA | |
| SCHEMBL19634816 | 0.80 | ROCK2 (0.57) | ROCK2CYP3A4CYP2C9ROCK1HPGD | |
| SCHEMBL5753081 | 0.80 | NPC1 (0.79) | ROCK2CYP3A4CYP2C9ROCK1GAA | |
| SCHEMBL307152 | 0.79 | ROCK2 (1.00) | ROCK2CYP3A4ROCK1LMNANPC1 | |
| SCHEMBL19634574 | 0.79 | KDM1A (0.55) | ROCK2CYP3A4CYP2C9ROCK1HPGD | |
| SCHEMBL11760394 | 0.78 | POLB (0.69) | HPGDNPC1RAB9A | |
| SCHEMBL8324748 | 0.78 | TAS1R3 (0.64) | ROCK2HPGDLMNAGAATP53 | |
| SCHEMBL15888426 | 0.77 | ROCK2 (0.77) | ROCK2CYP3A4CYP2C9ROCK1LMNA | |
| SCHEMBL3609921 | 0.77 | ROCK2 (0.78) | ROCK2CYP3A4CYP2C9ROCK1LMNA | |
| SCHEMBL21015342 | 0.77 | ROCK2 (0.54) | ROCK2CYP3A4CYP2C9ROCK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041645-A1 | RHO KINASE INHIBITORS | CIT, ROCK1, RHOT2 | ROCK2 4/4885CYP3A4 2048/4885CYP2C9 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.